Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
December 30, 2019
RegMed Investors’ (RMi) closing bell: a ringside seat to share price destruction
December 30, 2019
RegMed Investors’ (RMi) pre-open: almost there, closing to year’s end
December 27, 2019
RegMed Investors’ (RMi) closing bell: another slippery slope and sliding sector as risk defines the investment pattern
December 26, 2019
RegMed Investors’ (RMi) closing bell: the sector tripped after all the good cheer
December 15, 2019
RegMed Investors’ (RMi) closing bell: buying the rumors, selling speculation as the sector gets slammed
December 15, 2019
RegMed Investors’ (RMi) pre-open: Friday, the thirteenth
December 9, 2019
RegMed Investors’ (RMi) closing bell: selling pressures
December 3, 2019
RegMed Investors’ (RMi) closing bell: sector rolls as Audentes Therapeutics’ (BOLD) acquisition stimulates interest in gene therapy
December 2, 2019
RegMed Investors’ (RMi) closing bell: right again as the sector dives
November 29, 2019
RegMed Investors’ (RMi) closing bell: an early and positive sector close
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors